PatientsLikeMe has lured Jason Johnson away from Merck. Johnson is leaving Merck after 14 years at the Big Pharma to head up R&D at PatientsLikeMe, a role which gives him responsibility for efforts to extract insights from patient-reported data.
Israel has become the latest country to disclose plans to create a population-scale database of linked genetic and clinical records. The current plan is reminiscent of the United Kingdom's 100,000 Genomes Project, with Israel considering working with tech firms to create a database of patients with rare genetic diseases.
Regeneron Pharmaceuticals is lobbying for the exome sequencing database it is building with Geisinger Health System to become the linchpin of President Obama's Precision Medicine program.
The Allen Institute for Brain Science has released an online database of neuron cell types, building blocks it thinks will lead to the creation of computer models of healthy brains. Publication of the free database marks an important, early milestone for the research program triggered by a $300 million donation from Microsoft co-founder Paul Allen in 2012.
AstraZeneca is digging through the genomes of 80,000 people in search of genes linked to cardiovascular diseases and diabetes. The project is a collaboration with the Montreal Heart Institute, which will genotype 80,000 samples from AstraZeneca's biobank of blood and tissue samples.
U.S. CRO Theorem Clinical Research is investing in its overseas infrastructure, setting up a new clinical supplies facility in Germany to speed up trials on the continent.
Global CRO QPS Holdings opened a new lab devoted to in vitro research, setting up shop in Fargo, ND, with eyes on early-stage partnerships.
Despite years of efforts from academia and the industry, including Merck, no FDA-approved West Nile virus vaccine exists. Scientists from Oregon Health & Science University are looking to change that.
Many delivery platforms are based in part on organisms existing in nature, such as bacteria or viruses, and now researchers at Massachusetts General Hospital have turned to the common Escherichia coli bacterium and instilled it with a natural ability to transport proteins.
Pfizer and 23andMe have begun enrolling people in their lupus study. The partners aim to recruit 5,000 people into the study of the genetics of lupus over the next 12 months, in part by asking existing 23andMe customers to participate.